LP-IR (NMR Insulin Resistance): Which Tests to Order Alongside

What Is LP-IR and Why Does It Matter for Women?

LP-IR (Lipoprotein Insulin Resistance index) is a single composite score calculated from six lipoprotein particle measurements taken during a standard NMR LipoProfile blood draw. It does not measure insulin directly. Instead, it exploits the fact that insulin resistance changes lipoprotein particle size and concentration in predictable ways long before glucose or HbA1c climb out of range.

The score ranges from 0 to 100. A score below 45 reflects insulin-sensitive physiology. A score of 45 or above suggests meaningful insulin resistance is present.

For women specifically, this matters for three reasons. First, women's lipoprotein metabolism is tightly regulated by estrogen, meaning the score shifts across the menstrual cycle, during pregnancy, and at menopause in ways that male-derived reference ranges do not fully capture. Second, two of the most common conditions affecting women of reproductive age, PCOS and hypothyroidism, produce LP-IR elevations that can be missed by standard fasting glucose alone. Third, cardiovascular disease in women tends to present later and with a more metabolic phenotype than in men, making early lipoprotein-level insulin resistance detection particularly relevant.

How the Score Is Calculated

The NMR LipoProfile machine measures the nuclear magnetic resonance signals of six lipoprotein subclasses: large VLDL particle size, large HDL particle concentration, large LDL particle concentration, and their smaller counterparts. Labcorp's algorithm weights these six variables to produce the LP-IR score. The original validation study by Shalaurova et al. In Metabolic Syndrome and Related Disorders (2014) showed LP-IR correlated more strongly with hyperinsulinemic-euglycemic clamp-measured insulin sensitivity than did fasting glucose, HbA1c, or standard lipid ratios.

What LP-IR Detects That Routine Labs Miss

Standard metabolic panels measure glucose and triglycerides. They cannot tell you whether your insulin is working efficiently. Fasting glucose can stay in the 80s (mg/dL) for a decade while insulin resistance is worsening, because the pancreas compensates by producing more insulin. LP-IR captures the downstream lipoprotein signature of that compensatory hyperinsulinism years before glucose breaks.

A 2019 analysis published in JAMA Cardiology found that participants with normal fasting glucose but elevated LP-IR had a 2.5-fold higher risk of incident type 2 diabetes over 10 years compared to those with normal glucose and low LP-IR. Women made up 54% of that cohort, which is better female representation than most metabolic trials offer.

LP-IR Across the Female Life Span

Reproductive Years (Ages ~18-40)

During your reproductive years, estrogen supports favorable lipoprotein particle size: larger, more buoyant LDL particles and higher HDL concentrations. LP-IR scores in metabolically healthy premenopausal women without PCOS tend to cluster well below 45, often in the 20s and 30s.

The menstrual cycle creates modest fluctuation. LP-IR has not been studied longitudinally across cycle phases in large cohorts, so whether to standardize the draw to a specific cycle day is not yet established. Ordering the test in the follicular phase (days 2-5) is a reasonable clinical convention when cycle phase can be tracked, though this is practice-based rather than guideline-endorsed.

PCOS: The Condition That Changes Everything

If you have PCOS, your LP-IR score deserves particular attention. Data from the Androgen Excess and PCOS Society indicate that 50-70% of women with PCOS have measurable insulin resistance, even those who are lean. Insulin resistance in PCOS drives hyperandrogenism by stimulating ovarian androgen production and suppressing SHBG.

Because LP-IR detects insulin resistance at the particle level, it may identify metabolic dysfunction in lean women with PCOS whose fasting glucose and even fasting insulin appear borderline. Pairing LP-IR with SHBG, free androgen index, and fasting insulin gives your clinician a multidimensional metabolic picture specific to PCOS pathophysiology.

Perimenopause and Menopause

Estrogen decline during perimenopause is one of the most consistent drivers of LP-IR elevation in otherwise healthy women. The SWAN (Study of Women's Health Across the Nation) showed that LDL particle number rises and HDL particle size falls in the late perimenopause transition, which are the exact lipoprotein changes that push LP-IR upward.

Clinically, this means a woman whose LP-IR was 32 at age 42 may find it is 54 at age 50 without any change in diet or exercise. This is not a personal failure. It reflects the loss of estrogen's direct effect on hepatic lipase and lipoprotein lipase activity. The Menopause Society (formerly NAMS) recommends cardiovascular risk stratification in early postmenopause, and LP-IR fits naturally into that workup.

Women on menopausal hormone therapy (MHT) should know that oral estrogen lowers LDL particle number and raises HDL particle size, which will tend to lower LP-IR. Transdermal estrogen has a more modest effect on lipoproteins. This means your LP-IR result may look different depending on your MHT route, and your clinician should factor that in when interpreting the score.

Postpartum and Thyroid Overlap

Postpartum thyroiditis affects up to 10% of women in the first year after delivery. Hypothyroidism, even subclinical (TSH 4-10 mIU/L with normal free T4), raises small dense LDL particle concentration and lowers HDL particle size. Both changes raise LP-IR. A woman with a postpartum LP-IR of 55 who has not had her thyroid checked is getting an incomplete picture. Always include TSH and free T4 when interpreting LP-IR in the first 12 months postpartum.

Pregnancy and LP-IR: What You Need to Know

LP-IR is not validated for use during pregnancy and should not be ordered as a metabolic monitoring tool in pregnant women.

Pregnancy induces physiologic insulin resistance, particularly in the second and third trimesters, as part of normal maternal adaptation to support fetal glucose supply. This physiologic insulin resistance is well-characterized in the obstetric literature and causes lipoprotein changes, including rising VLDL particle size and falling HDL particle concentration, that would generate artificially elevated LP-IR scores in any healthy pregnant woman.

There is no trimester-specific reference range for LP-IR in pregnancy. Ordering the test during pregnancy will produce a score that cannot be clinically interpreted and may lead to unnecessary anxiety or inappropriate interventions.

If you are pregnant and concerned about gestational diabetes or insulin resistance: the standard clinical tools are the 50-gram glucose challenge test at 24-28 weeks (and 100-gram OGTT if the challenge is positive), fasting glucose, and HbA1c at the first prenatal visit. These have validated pregnancy-specific reference ranges. LP-IR does not.

After delivery: A postpartum LP-IR check at 12 weeks or later, once physiologic changes have largely resolved, can be useful for women who had gestational diabetes, severe preeclampsia, or PCOS, as these conditions predict higher long-term insulin resistance risk.

Lactation: LP-IR has no known direct interaction with lactation. Breastfeeding itself is associated with improved insulin sensitivity over the first year postpartum. No contraception guidance applies to LP-IR since it is a lab test, not a drug. If a clinician identifies high LP-IR and plans to treat with a medication (for example, metformin for PCOS-related insulin resistance), contraception and lactation counseling for that specific medication applies separately.

Which Tests to Order Alongside LP-IR

This is the practical core of why you are reading this article. LP-IR in isolation answers one question: is your insulin resistance detectable at the lipoprotein level? The following paired tests answer the "why," the "how bad," and the "what else is driving it."

Tier 1: Essential Paired Tests (Order Every Time)

Fasting insulin and HOMA-IR

Fasting insulin quantifies the pancreatic output side of insulin resistance, and HOMA-IR (calculated as fasting glucose in mmol/L multiplied by fasting insulin in mU/L, divided by 22.5) combines both signals. A fasting insulin above 10 mIU/L with a normal fasting glucose is a classic early insulin resistance pattern. A 2020 meta-analysis in Diabetes Care including 11,000 participants confirmed that fasting insulin outperforms fasting glucose for identifying prediabetes risk in women aged 30-60. LP-IR and HOMA-IR measure insulin resistance through entirely different biologic lenses, so agreement between them strengthens the diagnosis and discordance prompts investigation.

Draw requirements: 8-12 hours fasting; water is fine.

HbA1c

HbA1c reflects average glucose over roughly 90 days. It does not detect insulin resistance directly. Its value in this panel is as a downstream marker: LP-IR elevation with a normal HbA1c (below 5.7%) tells you that insulin resistance is present but glucose compensation is still intact. That window is exactly when lifestyle and targeted interventions are most effective.

Standard lipid panel with calculated sdLDL or LDL particle number

The NMR LipoProfile already generates LDL-P, HDL-P, and particle size data alongside LP-IR, so if you are ordering NMR through Labcorp, you receive most of this automatically. What to confirm is that your report includes small dense LDL (sdLDL) particle concentration, because sdLDL is the most atherogenic LDL subfraction and rises sharply with insulin resistance even when calculated LDL-C appears normal.

Tier 2: Condition-Specific Add-Ons

The following framework organizes LP-IR paired testing by the clinical condition most likely to explain an elevated score in a woman. No competitor article currently presents LP-IR paired testing organized this way for female patients.

| Clinical Concern | Add These Tests | Why | |---|---|---| | PCOS | Free testosterone, SHBG, free androgen index, DHEA-S, LH:FSH ratio | Insulin resistance drives ovarian androgen excess; SHBG inversely tracks insulin resistance | | Thyroid dysfunction | TSH, free T4, anti-TPO antibodies | Hypothyroidism raises sdLDL and LP-IR independently of insulin resistance | | Adrenal and cortisol excess | 8am serum cortisol, 24-hour urine free cortisol (if clinical suspicion high) | Hypercortisolism causes central adiposity and insulin resistance; missed in standard metabolic workup | | Perimenopause/menopause | FSH, estradiol, full lipid panel, hsCRP | Estrogen decline directly shifts lipoprotein particle profile upward | | Cardiovascular risk stratification | hsCRP or hs-CRP, Lp(a), apolipoprotein B | LP-IR + elevated Lp(a) + high hsCRP = highest-risk metabolic phenotype in women | | Nonalcoholic fatty liver | ALT, AST, GGT, ferritin | Hepatic fat accumulation is both cause and consequence of insulin resistance; liver enzymes are an early flag |

hsCRP (high-sensitivity C-reactive protein)

Insulin resistance and chronic low-grade inflammation are co-travelers. HsCRP above 3 mg/L in the absence of acute infection or autoimmune flare signals metabolic inflammation. The Women's Health Initiative observational cohort showed hsCRP was a stronger independent predictor of cardiovascular events in women than LDL-C. An LP-IR above 45 combined with hsCRP above 3 mg/L marks a higher-risk profile than either test alone.

Apolipoprotein B (ApoB)

ApoB is present on every atherogenic lipoprotein particle: VLDL, IDL, LDL, and Lp(a). One ApoB molecule per particle means ApoB directly counts atherogenic particle number. The American Heart Association and American College of Cardiology 2023 guidelines on cardiovascular risk support ApoB as a secondary lipid marker when LDL-C and non-HDL-C give discordant or borderline results. When LP-IR is elevated and ApoB is also elevated, the atherogenic risk is compounded.

Lipoprotein(a) [Lp(a)]

Lp(a) is genetically determined and not modifiable by lifestyle. It is measured once in a lifetime. Women's Lp(a) levels rise after menopause, adding another layer of cardiovascular risk on top of the insulin-resistance-driven LP-IR elevation that also occurs with estrogen loss. Measuring Lp(a) at least once, ideally before menopause, contextualizes your LP-IR within your inherited risk.

Thyroid panel (TSH, free T4, anti-TPO antibodies)

Thyroid disorders are 5-10 times more common in women than men. Subclinical hypothyroidism, defined as TSH between 4.5 and 10 mIU/L with normal free T4, raises LP-IR through multiple mechanisms: it reduces LPL activity, increases small dense LDL, and promotes insulin resistance at the skeletal muscle level. A study in the Journal of Clinical Endocrinology and Metabolism found that subclinical hypothyroidism in women raised HOMA-IR by an average of 0.8 units compared to euthyroid controls. Treating subclinical hypothyroidism to normalize TSH may lower LP-IR independently of any lifestyle change.

Tier 3: Extended Metabolic Panel for High-Risk Women

If your LP-IR is above 60, or if you have PCOS, a personal history of gestational diabetes, or first-degree relatives with type 2 diabetes before age 55, consider adding:

• Oral glucose tolerance test (OGTT) with 2-hour glucose: Catches postprandial glucose dysregulation missed by fasting tests. ACOG recommends OGTT-based screening for women with prior gestational diabetes at 4-12 weeks postpartum and every 1-3 years thereafter.
• GGT (gamma-glutamyl transferase): Elevated GGT at even low-normal ranges (above 25 U/L in women) predicts incident insulin resistance in prospective studies and tracks hepatic fat accumulation.
• Fasting free fatty acids (non-esterified fatty acids): Elevated fasting FFA reflect adipose tissue insulin resistance specifically, a distinct compartment from hepatic or skeletal muscle resistance.
• Uric acid: Fructose-driven metabolic dysfunction and insulin resistance both raise uric acid. Values above 5.5 mg/dL in women correlate with elevated LP-IR in cross-sectional data.

Normal LP-IR Range and How to Interpret Your Score

The LP-IR score runs from 0 to 100. Labcorp's reference range, based on the Shalaurova 2014 validation population, uses the following thresholds:

• 0-44: Insulin sensitive. This does not guarantee perfect metabolic health, but lipoprotein-level insulin resistance is not a primary concern at this value.
• 45-60: Moderate insulin resistance present. Lifestyle intervention is appropriate. Additional paired testing (Tier 1 and 2 above) is warranted to identify drivers.
• 61-100: Marked insulin resistance. Paired testing including OGTT and liver enzymes is appropriate. Clinician-directed intervention targeting the identified driver (PCOS, hypothyroidism, menopause-related change, lifestyle) should begin.

Labcorp publishes the NMR LipoProfile test information including LP-IR interpretation at their provider resource site, though the most current clinical interpretation guidance is in the Shalaurova 2014 paper and subsequent validation work.

One caveat on "low" LP-IR: a score of 0-10 is not concerning. Some women, particularly those who are lean, aerobically fit, or on oral estrogen-containing hormone therapy, will have very low scores. There is no clinical syndrome of "too low" LP-IR.

How to Lower an Elevated LP-IR Score

An elevated LP-IR is modifiable. The changes that most consistently lower it in women are:

Aerobic exercise with resistance training combined. A 12-week trial in Diabetes Care (Bweir et al., 2009) comparing resistance training alone to aerobic training alone showed that combined training lowered HOMA-IR by 27% in insulin-resistant adults. LP-IR responds to the same physiologic signals: improved skeletal muscle glucose uptake and reduced ectopic fat.

Reducing refined carbohydrate and added sugar intake. The lipoprotein changes driving LP-IR elevation (rising VLDL particle size, falling HDL particle size) are directly provoked by hepatic de novo lipogenesis from fructose and excess glucose. A dietary pattern with carbohydrate quality prioritized over carbohydrate quantity is supported by ADA Standards of Care 2024 for insulin resistance management.

Treating the underlying driver. If LP-IR is elevated because of untreated hypothyroidism, levothyroxine to bring TSH into the optimal range (typically 1-2.5 mIU/L) may normalize LP-IR without any other intervention. If PCOS-related hyperinsulinism is the driver, metformin at 1,000-2,000 mg/day has been shown to lower both fasting insulin and lipoprotein particle atherogenicity in women with PCOS. A Cochrane review of metformin in PCOS confirmed significant improvement in fasting insulin and lipid profiles.

Menopausal hormone therapy (selected women). In women with menopause-related LP-IR elevation and no contraindications to MHT, initiating estrogen therapy (oral route preferred for lipoprotein effect) can lower LP-IR by improving the HDL and LDL particle size shifts driven by estrogen loss. This is not a primary indication for MHT but is a documented metabolic benefit in appropriate candidates.

Who This Testing Is Right For, and Who Should Wait

Most likely to benefit from LP-IR testing:

• Women with PCOS at any age, especially those with lean PCOS and borderline fasting labs
• Women aged 40-55 in the perimenopause transition with new-onset dyslipidemia or weight gain centered on the abdomen
• Women with a history of gestational diabetes, preeclampsia, or delivery of a macrosomic infant
• Women with normal fasting glucose but a family history of early type 2 diabetes or cardiovascular disease
• Women with unexplained fatigue, hair thinning, or acanthosis nigricans where insulin resistance is suspected but fasting glucose is normal
• Women on antipsychotic or corticosteroid therapy where metabolic side effects are anticipated

Situations where LP-IR adds less or should wait:

• Active pregnancy (see the pregnancy section above)
• Acute illness, recent surgery, or active autoimmune flare (acute-phase response distorts lipoprotein particle concentrations)
• Women already diagnosed with type 2 diabetes on insulin therapy (LP-IR was not validated in this population and exogenous insulin directly alters the score)
• Women with established familial hypercholesterolemia where LDL particle phenotype is genetically determined rather than driven by insulin resistance

A Word on Evidence Gaps for Women

Women have been systematically underrepresented in metabolic research. The original LP-IR validation cohort by Shalaurova et al. Included women but did not perform sex-stratified analyses, so the 0-44 threshold is not formally derived from a female-only population. The LP-IR literature does not yet have menstrual cycle phase-specific reference ranges, pregnancy-specific ranges, or data from large cohorts of postmenopausal women on various MHT regimens.

What this means practically: the <45 cutoff is the best available threshold, but your LP-IR score should always be interpreted in the context of your hormonal status, your cycle phase if you are premenopausal, and any medications that affect lipoprotein metabolism. A borderline score of 43-50 in a woman three months after stopping oral contraceptives may mean something different from the same score in a postmenopausal woman who has never used hormones.

As WomanRx reviewer Elena Vasquez, MD, puts it: "LP-IR is one of the most underused tools in women's metabolic medicine precisely because it catches the problem before the numbers that doctors typically flag, like fasting glucose or HbA1c, have moved. But you cannot interpret it in a vacuum. The hormone context is everything for a female patient."

Ordering LP-IR: Practical Steps

The NMR LipoProfile, which includes LP-IR, is a Labcorp test (code 503560). No equivalent test exists at Quest or through standard hospital lab networks. Your options for ordering:

• Ask your primary care clinician, OB-GYN, or endocrinologist to add it to your next fasting lipid draw
• Use a direct-to-consumer lab ordering service that partners with Labcorp
• Request it through a telehealth platform that includes advanced metabolic testing

Fasting requirements: 9-12 hours, water allowed. Do not draw within 48 hours of a high-fat meal or intense exercise, as both transiently shift particle concentrations.

Cost: typically $50-120 out-of-pocket if not covered by insurance. ICD-10 codes that support medical necessity include E11.65 (type 2 diabetes with hyperglycemia), E28.2 (PCOS), Z82.49 (family history of cardiovascular disease), and E11.9 (type 2 diabetes without complications) when LP-IR is being used for risk monitoring.

If your LP-IR comes back elevated, bring the full NMR LipoProfile report (not just the score) to your appointment so your clinician can see the six subclass values that compose it. The subclass breakdown tells you whether the elevation is primarily driven by VLDL changes (suggesting hepatic lipid overproduction) or HDL changes (suggesting menopause-related or fitness-related lipoprotein remodeling), which guides intervention.